Literature DB >> 19749986

Dalbavancin (zeven), a novel glycopeptide for resistant gram-positive organisms.

Jennifer Colabella, Larisa Chagan.   

Abstract

Entities:  

Year:  2008        PMID： 19749986      PMCID： PMC2730060     

Source DB:  PubMed          Journal:  P T        ISSN： 1052-1372


× No keyword cloud information.
  36 in total

Review 1.  Staphylococcus aureus bone and joint infection.

Authors:  S Mandal; A R Berendt; S J Peacock
Journal:  J Infect       Date:  2002-04       Impact factor: 6.072

Review 2.  Dalbavancin: a novel lipoglycopeptide antibacterial.

Authors:  Scott D Pope; Andrew M Roecker
Journal:  Pharmacotherapy       Date:  2006-07       Impact factor: 4.705

3.  Antimicrobial spectrum and potency of dalbavancin tested against clinical isolates from Europe and North America (2003): initial results from an international surveillance protocol.

Authors:  R N Jones; T R Fritsche; H S Sader; B P Goldstein
Journal:  J Chemother       Date:  2005-12       Impact factor: 1.714

4.  Activity of dalbavancin tested against Staphylococcus spp. and beta-hemolytic Streptococcus spp. isolated from 52 geographically diverse medical centers in the United States.

Authors:  Douglas J Biedenbach; James E Ross; Thomas R Fritsche; Helio S Sader; Ronald N Jones
Journal:  J Clin Microbiol       Date:  2007-01-10       Impact factor: 5.948

5.  Spectrum and potency of dalbavancin tested against 3322 Gram-positive cocci isolated in the United States Surveillance Program (2004).

Authors:  Ronald N Jones; Matthew G Stilwell; Helio S Sader; Thomas R Fritsche; Beth P Goldstein
Journal:  Diagn Microbiol Infect Dis       Date:  2006-01-19       Impact factor: 2.803

6.  Comparison of mortality risk associated with bacteremia due to methicillin-resistant and methicillin-susceptible Staphylococcus aureus.

Authors:  Simone Shurland; Min Zhan; Douglas D Bradham; Mary-Claire Roghmann
Journal:  Infect Control Hosp Epidemiol       Date:  2007-02-15       Impact factor: 3.254

7.  Activity of dalbavancin against staphylococci and streptococci, assessed by BSAC and NCCLS agar dilution methods.

Authors:  Shazad Mushtaq; Marina Warner; Alan P Johnson; David M Livermore
Journal:  J Antimicrob Chemother       Date:  2004-08-20       Impact factor: 5.790

8.  Once-weekly dalbavancin versus standard-of-care antimicrobial regimens for treatment of skin and soft-tissue infections.

Authors:  Elyse Seltzer; Mary Beth Dorr; Beth P Goldstein; Marc Perry; James A Dowell; Tim Henkel
Journal:  Clin Infect Dis       Date:  2003-10-17       Impact factor: 9.079

9.  Efficacy of dalbavancin against methicillin-resistant Staphylococcus aureus in the rat granuloma pouch infection model.

Authors:  Daniela Jabés; Gianpaolo Candiani; Gabriella Romanó; Cristina Brunati; Simona Riva; Marco Cavaleri
Journal:  Antimicrob Agents Chemother       Date:  2004-04       Impact factor: 5.191

10.  Activities of dalbavancin in vitro and in a rabbit model of experimental endocarditis due to Staphylococcus aureus with or without reduced susceptibility to vancomycin and teicoplanin.

Authors:  Agnès Lefort; Juliette Pavie; Louis Garry; Françoise Chau; Bruno Fantin
Journal:  Antimicrob Agents Chemother       Date:  2004-03       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.